Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer

Ernst Kubista, John Glaspy, Frankie Ann Holmes, Michael D. Green, James Hackett, Theresa Neumann, Franklin Marques, Luis Meza, David Miles, Melvin Moore, Joyce O'Shaughnessy, Martine J. Piccart, Gary E. Richardson, Hellmutt Samonigg, Armando Santoro, Michael Savin, Martin Ronald Schaafsma, Salvatore Siena, Jeffrey Shogan, Svetislava Vukelja & 1 others Israel Wiznitzer

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Bone pain is a common side effect of treatment with filgrastim. Pegfilgrastim is a pegylated long-acting analogue of filgrastim that is administered once per chemotherapy cycle. The profile of prospectively defined, patient-reported bone pain judged by the investigators as related to study drug was analyzed retrospectively for each drug using data from two comparable phase III trials. These multicenter, randomized, double-blind, noninferiority trials compared once-per-cycle pegfilgrastim (6 mg, study 1 or 100 μg/kg, study 2) to daily filgrastim 5 μg/kg in patients with stage II-IV breast cancer undergoing multiple cycles of myelosuppressive chemotherapy (doxorubicin/docetaxel). Subcutaneous once-per-cycle pegfilgrastim 6-mg and 100-μg/kg doses were administered to 76 and 150 patients, respectively; subcutaneous daily filgrastim 5 μg/kg was administered to a total of 227 patients. Because bone pain in study 1 was higher (P = 0.044) in every cycle compared with study 2, all analyses were performed separately for each study. No statistically significant differences in incidence, severity, or duration were observed between patients receiving either once-per-cycle pegfilgrastim or daily filgrastim in either study. Bone pain incidence and severity were significantly greater (P < 0.001) in cycle 1 of both studies compared with later cycles. Among patients with bone pain, a trend towards earlier onset with pegfilgrastim was observed but was not associated with increased bone pain severity or duration. In patients who received a fixed 6-mg dose of pegfilgrastim, the overall bone pain incidence was similar when analyzed by body weight (< 60 kg, 60-100 kg, > 100 kg). No patients were withdrawn from either study for bone pain.

Original languageEnglish
Pages (from-to)391-398
Number of pages8
JournalClinical Breast Cancer
Volume3
Issue number6
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Breast Neoplasms
Bone and Bones
Pain
docetaxel
Drug Therapy
Incidence
Pharmaceutical Preparations
Doxorubicin
Filgrastim
pegfilgrastim
Research Personnel
Therapeutics

Keywords

  • Fixed-weight dosing
  • Neutrophil growth factor
  • Phase III clinical trial
  • Retrospective analysis

ASJC Scopus subject areas

  • Cancer Research

Cite this

Kubista, E., Glaspy, J., Holmes, F. A., Green, M. D., Hackett, J., Neumann, T., ... Wiznitzer, I. (2003). Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clinical Breast Cancer, 3(6), 391-398.

Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. / Kubista, Ernst; Glaspy, John; Holmes, Frankie Ann; Green, Michael D.; Hackett, James; Neumann, Theresa; Marques, Franklin; Meza, Luis; Miles, David; Moore, Melvin; O'Shaughnessy, Joyce; Piccart, Martine J.; Richardson, Gary E.; Samonigg, Hellmutt; Santoro, Armando; Savin, Michael; Schaafsma, Martin Ronald; Siena, Salvatore; Shogan, Jeffrey; Vukelja, Svetislava; Wiznitzer, Israel.

In: Clinical Breast Cancer, Vol. 3, No. 6, 01.01.2003, p. 391-398.

Research output: Contribution to journalArticle

Kubista, E, Glaspy, J, Holmes, FA, Green, MD, Hackett, J, Neumann, T, Marques, F, Meza, L, Miles, D, Moore, M, O'Shaughnessy, J, Piccart, MJ, Richardson, GE, Samonigg, H, Santoro, A, Savin, M, Schaafsma, MR, Siena, S, Shogan, J, Vukelja, S & Wiznitzer, I 2003, 'Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer', Clinical Breast Cancer, vol. 3, no. 6, pp. 391-398.
Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T et al. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clinical Breast Cancer. 2003 Jan 1;3(6):391-398.
Kubista, Ernst ; Glaspy, John ; Holmes, Frankie Ann ; Green, Michael D. ; Hackett, James ; Neumann, Theresa ; Marques, Franklin ; Meza, Luis ; Miles, David ; Moore, Melvin ; O'Shaughnessy, Joyce ; Piccart, Martine J. ; Richardson, Gary E. ; Samonigg, Hellmutt ; Santoro, Armando ; Savin, Michael ; Schaafsma, Martin Ronald ; Siena, Salvatore ; Shogan, Jeffrey ; Vukelja, Svetislava ; Wiznitzer, Israel. / Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. In: Clinical Breast Cancer. 2003 ; Vol. 3, No. 6. pp. 391-398.
@article{379000970744405d9f0a041e8b10673f,
title = "Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer",
abstract = "Bone pain is a common side effect of treatment with filgrastim. Pegfilgrastim is a pegylated long-acting analogue of filgrastim that is administered once per chemotherapy cycle. The profile of prospectively defined, patient-reported bone pain judged by the investigators as related to study drug was analyzed retrospectively for each drug using data from two comparable phase III trials. These multicenter, randomized, double-blind, noninferiority trials compared once-per-cycle pegfilgrastim (6 mg, study 1 or 100 μg/kg, study 2) to daily filgrastim 5 μg/kg in patients with stage II-IV breast cancer undergoing multiple cycles of myelosuppressive chemotherapy (doxorubicin/docetaxel). Subcutaneous once-per-cycle pegfilgrastim 6-mg and 100-μg/kg doses were administered to 76 and 150 patients, respectively; subcutaneous daily filgrastim 5 μg/kg was administered to a total of 227 patients. Because bone pain in study 1 was higher (P = 0.044) in every cycle compared with study 2, all analyses were performed separately for each study. No statistically significant differences in incidence, severity, or duration were observed between patients receiving either once-per-cycle pegfilgrastim or daily filgrastim in either study. Bone pain incidence and severity were significantly greater (P < 0.001) in cycle 1 of both studies compared with later cycles. Among patients with bone pain, a trend towards earlier onset with pegfilgrastim was observed but was not associated with increased bone pain severity or duration. In patients who received a fixed 6-mg dose of pegfilgrastim, the overall bone pain incidence was similar when analyzed by body weight (< 60 kg, 60-100 kg, > 100 kg). No patients were withdrawn from either study for bone pain.",
keywords = "Fixed-weight dosing, Neutrophil growth factor, Phase III clinical trial, Retrospective analysis",
author = "Ernst Kubista and John Glaspy and Holmes, {Frankie Ann} and Green, {Michael D.} and James Hackett and Theresa Neumann and Franklin Marques and Luis Meza and David Miles and Melvin Moore and Joyce O'Shaughnessy and Piccart, {Martine J.} and Richardson, {Gary E.} and Hellmutt Samonigg and Armando Santoro and Michael Savin and Schaafsma, {Martin Ronald} and Salvatore Siena and Jeffrey Shogan and Svetislava Vukelja and Israel Wiznitzer",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "3",
pages = "391--398",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer

AU - Kubista, Ernst

AU - Glaspy, John

AU - Holmes, Frankie Ann

AU - Green, Michael D.

AU - Hackett, James

AU - Neumann, Theresa

AU - Marques, Franklin

AU - Meza, Luis

AU - Miles, David

AU - Moore, Melvin

AU - O'Shaughnessy, Joyce

AU - Piccart, Martine J.

AU - Richardson, Gary E.

AU - Samonigg, Hellmutt

AU - Santoro, Armando

AU - Savin, Michael

AU - Schaafsma, Martin Ronald

AU - Siena, Salvatore

AU - Shogan, Jeffrey

AU - Vukelja, Svetislava

AU - Wiznitzer, Israel

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Bone pain is a common side effect of treatment with filgrastim. Pegfilgrastim is a pegylated long-acting analogue of filgrastim that is administered once per chemotherapy cycle. The profile of prospectively defined, patient-reported bone pain judged by the investigators as related to study drug was analyzed retrospectively for each drug using data from two comparable phase III trials. These multicenter, randomized, double-blind, noninferiority trials compared once-per-cycle pegfilgrastim (6 mg, study 1 or 100 μg/kg, study 2) to daily filgrastim 5 μg/kg in patients with stage II-IV breast cancer undergoing multiple cycles of myelosuppressive chemotherapy (doxorubicin/docetaxel). Subcutaneous once-per-cycle pegfilgrastim 6-mg and 100-μg/kg doses were administered to 76 and 150 patients, respectively; subcutaneous daily filgrastim 5 μg/kg was administered to a total of 227 patients. Because bone pain in study 1 was higher (P = 0.044) in every cycle compared with study 2, all analyses were performed separately for each study. No statistically significant differences in incidence, severity, or duration were observed between patients receiving either once-per-cycle pegfilgrastim or daily filgrastim in either study. Bone pain incidence and severity were significantly greater (P < 0.001) in cycle 1 of both studies compared with later cycles. Among patients with bone pain, a trend towards earlier onset with pegfilgrastim was observed but was not associated with increased bone pain severity or duration. In patients who received a fixed 6-mg dose of pegfilgrastim, the overall bone pain incidence was similar when analyzed by body weight (< 60 kg, 60-100 kg, > 100 kg). No patients were withdrawn from either study for bone pain.

AB - Bone pain is a common side effect of treatment with filgrastim. Pegfilgrastim is a pegylated long-acting analogue of filgrastim that is administered once per chemotherapy cycle. The profile of prospectively defined, patient-reported bone pain judged by the investigators as related to study drug was analyzed retrospectively for each drug using data from two comparable phase III trials. These multicenter, randomized, double-blind, noninferiority trials compared once-per-cycle pegfilgrastim (6 mg, study 1 or 100 μg/kg, study 2) to daily filgrastim 5 μg/kg in patients with stage II-IV breast cancer undergoing multiple cycles of myelosuppressive chemotherapy (doxorubicin/docetaxel). Subcutaneous once-per-cycle pegfilgrastim 6-mg and 100-μg/kg doses were administered to 76 and 150 patients, respectively; subcutaneous daily filgrastim 5 μg/kg was administered to a total of 227 patients. Because bone pain in study 1 was higher (P = 0.044) in every cycle compared with study 2, all analyses were performed separately for each study. No statistically significant differences in incidence, severity, or duration were observed between patients receiving either once-per-cycle pegfilgrastim or daily filgrastim in either study. Bone pain incidence and severity were significantly greater (P < 0.001) in cycle 1 of both studies compared with later cycles. Among patients with bone pain, a trend towards earlier onset with pegfilgrastim was observed but was not associated with increased bone pain severity or duration. In patients who received a fixed 6-mg dose of pegfilgrastim, the overall bone pain incidence was similar when analyzed by body weight (< 60 kg, 60-100 kg, > 100 kg). No patients were withdrawn from either study for bone pain.

KW - Fixed-weight dosing

KW - Neutrophil growth factor

KW - Phase III clinical trial

KW - Retrospective analysis

UR - http://www.scopus.com/inward/record.url?scp=0037301718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037301718&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 391

EP - 398

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -